安慰剂
内科学
胃肠病学
医学
益生元
菊粉
拟杆菌
肠道菌群
不利影响
随机对照试验
双歧杆菌
免疫学
生物
乳酸菌
病理
食品科学
替代医学
细菌
发酵
遗传学
作者
Camille Amadieu,Luca Maccioni,Sophie Leclercq,Audrey M. Neyrinck,Nathalie M. Delzenne,Philippe de Timary,Peter Stärkel
出处
期刊:EBioMedicine
[Elsevier BV]
日期:2022-04-28
卷期号:80: 104033-104033
被引量:19
标识
DOI:10.1016/j.ebiom.2022.104033
摘要
BackgroundEmerging evidence highlights that targeting the gut microbiota could be an interesting approach to improve alcohol liver disease due to its important plasticity. This study aimed to evaluate the effects of inulin supplementation on liver parameters in alcohol use disorder (AUD) patients (whole sample) and in a subpopulation with early alcohol-associated liver disease (eALD).MethodsFifty AUD patients, hospitalized for a 3-week detoxification program, were enrolled in a randomized, double-blind, placebo-controlled study and assigned to prebiotic (inulin) versus placebo for 17 days. Liver damage, microbial translocation, inflammatory markers and 16S rDNA sequencing were measured at the beginning (T1) and at the end of the study (T2).FindingsCompared to placebo, AST (β = 8.55, 95% CI [2.33:14.77]), ALT (β = 6.01, 95% CI [2.02:10.00]) and IL-18 (β = 113.86, 95% CI [23.02:204.71]) were statistically significantly higher in the inulin group in the whole sample at T2. In the eALD subgroup, inulin supplementation leads to specific changes in the gut microbiota, including an increase in Bifidobacterium and a decrease of Bacteroides. Despite those changes, AST (β = 14.63, 95% CI [0.91:28.35]) and ALT (β = 10.40, 95% CI [1.93:18.88]) at T2 were higher in the inulin group compared to placebo. Treatment was well tolerated without important adverse events or side effects.InterpretationThis pilot study shows that 17 days of inulin supplementation versus placebo, even though it induces specific changes in the gut microbiota, did not alleviate liver damage in AUD patients. Further studies with a larger sample size and duration of supplementation with adequate monitoring of liver parameters are needed to confirm these results. Gut2Brain study: https://clinicaltrials.gov/ct2/show/NCT03803709FundingFédération Wallonie-Bruxelles, FRS-FNRS, Fondation Saint-Luc.
科研通智能强力驱动
Strongly Powered by AbleSci AI